CagriSema曾被寄予厚望，诺和诺德将其定位为比司美格鲁肽更强效的继任者，且诺和诺德未来60%的 增长将来自于CagriSema。最新头对头数据的公布也意味着这一希望可能破灭。不过，诺和诺德称，计 划于今年下半年进行更高剂量的临床试验。 消息面上，诺和诺德新一代减重药CagriSema头对头比较礼来减重药替尔泊肽（Tirzepatide）的三期临床 试验结果显示，在84周内，CagriSema实现减重23%，疗效不及礼来替尔泊肽25.5%的减重效果。 股价受累 2月24日，据业内消息，诺和诺德宣布，自2027年1月1日起，旗下减重明星药（司美格鲁肽）在美国市 场的标价将下调50%，月费降至675美元。 在2月23日，欧洲股市开盘后，诺和诺德股价直线跳水，盘中一度暴跌超15%，创下2021年6月以来最低 水平。截至2月24日收盘，其股价为38.59美元/股，跌幅2.62%，总市值为1716亿美元。 新品研发不及预期，直接影响了诺和诺德股价。2024年6月，诺和诺德市值一度攀升至6500亿美元的历 史高点，成为欧洲市值最高的上市公司。当时，其市值不仅超越了德国软件巨头SAP，也超过了 LVMH、ASML等欧洲 ...

诺和诺德宣布大幅下调明星减肥药Wegovy及Ozempic在美国市场的标价，司美格鲁肽系列药物月度标价统一为675美元，降幅最高达50%，新定价 将于明年1月1日生效。此举标志着这家丹麦药企在肥胖症市场的竞争策略出现重大转向。 消息公布后，诺和诺德美股盘前下跌3%，礼来美股盘前一度跌逾4%。值得注意的是，诺和诺德本周一刚公布下一代药物CagriSema又一组令人失 望的试验数据，此后股价已累计下跌约19%。降价决定在此背景下出炉，进一步加剧市场担忧。 此次降价是诺和诺德在肥胖症市场竞争中失去领先地位后的主动应对。礼来竞品Zepbound目前标价为每月1086.37美元，诺和诺德统一定价至675 美元后，在标价层面形成明显价格优势。 诺和诺德美国业务负责人Jamey Millar表示，此次降价不会对公司净销售额产生直接影响，但对获得支付方认可持乐观态度。Millar曾任职于 UnitedHealth Group旗下药品福利管理机构Optum Rx，深谙美国药品定价策略。他表示： "支付方此前已公开呼吁降低药品标价，我有信心他们将接受并欢迎这些更低的标价。" 高免赔额计划患者受益最大 此次降价针对的是批发采购成本 ...

全球减肥药"霸主"诺和诺德因新药不及竞争对手礼来，迎来史诗级暴跌。 周一美股收盘，诺和诺德股价大跌超16%，股价跌至2021年6月以来的最低点，市值大幅缩水至1769.48亿美元。 相反，礼来因减肥药的升级，股价向上收涨4.8%，现总市值9986亿美元。 诺和诺德惨败 减肥药格局生变？ 全球医药圈突发巨震。 诺和诺德表示，正在探索更多试验方案来测试CagriSema，包括更高剂量组合方案。 这次减肥药双雄比拼的主角是：诺和诺德的CagriSema，和礼来的Zepbound。 不过，此次对决以诺和诺德惨败结束。 据诺和诺德发布声明称，接受标准剂量实验药物CagriSema治疗的受试者在84周后体重减轻了20.2%。 相比之下，礼来的替尔泊肽（Tirzepatide）减重效果为23.6%。 CagriSema为诺和诺德开发的一款复方药物，包含长效胰淀素（amylin）类似物Cagrilintide与GLP-1受体激动剂司美格鲁肽。 去年12月，诺和诺德向 FDA 提交了 CagriSema 的审批申请，该制药商表示预计将在 2026 年底做出决定。 诺和诺德原本寄希望于CagriSema能成为其现有药物Wegov ...

全球医药圈突发巨震。 这次减肥药双雄比拼的主角是：诺和诺德的CagriSema，和礼来的Zepbound。 不过，此次对决以诺和诺德惨败结束。 据诺和诺德发布声明称，接受标准剂量实验药物CagriSema治疗的受试者在84周后体重减轻了20.2%。 相比之下，礼来的替尔泊肽（Tirzepatide）减重效果为23.6%。 CagriSema为诺和诺德开发的一款复方药物，包含长效胰淀素（amylin）类似物Cagrilintide与GLP-1受体 激动剂司美格鲁肽。 全球减肥药"霸主"诺和诺德因新药不及竞争对手礼来，迎来史诗级暴跌。 周一美股收盘，诺和诺德股价大跌超16%，股价跌至2021年6月以来的最低点，市值大幅缩水至1769.48 亿美元。 相反，礼来因减肥药的升级，股价向上收涨4.8%，现总市值9986亿美元。 诺和诺德惨败 减肥药格局生变？ 对比来看，对手礼来则在突飞猛进。 去年12月，诺和诺德向 FDA 提交了 CagriSema 的审批申请，该制药商表示预计将在 2026 年底做出决 定。 诺和诺德原本寄希望于CagriSema能成为其现有药物Wegovy(将于2030年后专利到期)的强力继任者， ...

这些监管评论是在诺和诺德股价周三在哥本哈根暴跌17%之后发出的，此前该公司提前发布了2026年的悲观展望。 诺和诺德预计2026年的销售额和营业利润将下降5%至13%，这一前景远弱于分析师预期。 首席执行官Mike Doustdar在一份声明中表示："2026年，诺和诺德将在日益竞争激烈的市场中面临定价压力。" 他补充道："然而，我们对Wegovy片剂在美国推出后的早期良好接受度感到非常鼓舞，我们仍然相信我们有能力在未来几年推动销量增长。" 这一展望标志着该公司的明显转变，自2021年Wegovy推出以来，该公司的收入和利润已连续多年实现两位数增长，推动了减肥治疗需求的激 增，并使诺和诺德在2024年成为欧洲市值最高的上市公司。诺和诺德表示，其预测面临的压力反映了实际定价下降——特别是在美国——竞争 加剧，以及司美格鲁肽（Wegovy和Ozempic的活性成分）在美国以外某些市场的专利到期。 丹麦制药商诺和诺德公司(NYSE:NVO)(CSE:NOVOb)股价周五大幅上涨，收复了前两个交易日的部分重挫损失，此前美国食品药品监督管理局(FDA)表 示将打击大规模推广未获批准的仿制药。 该公司的美国存托凭证(AD ...

Core Viewpoint - Eli Lilly has significantly outperformed market expectations in Q4 revenue and profit, driven by the explosive sales of GLP-1 weight loss drugs, indicating a strong competitive position against Novo Nordisk in the weight loss drug market [1][3]. Financial Performance - In Q4, Eli Lilly reported revenue of $19.3 billion, a 43% year-over-year increase, surpassing analyst expectations of $18 billion [5]. - Non-GAAP EPS for Q4 was $7.54, up 42% year-over-year, exceeding market expectations of $6.73 [5]. - The strong performance is attributed to the robust demand for diabetes drug Mounjaro and weight loss drug Zepbound, with Zepbound's total prescriptions surpassing Novo Nordisk's Wegovy [5]. Future Outlook - Eli Lilly projects 2026 revenue between $80 billion and $83 billion, significantly above Wall Street's average expectation of $77.7 billion [7]. - Adjusted EPS is expected to be between $33.50 and $35.00, also exceeding analyst expectations of $33.08 [7]. - The company is leveraging its patent protection, aggressive capacity expansion, and upcoming oral formulations to maintain a competitive edge [7]. Key Products - Mounjaro and Zepbound together contributed over 60% of total revenue in Q4, with combined revenue exceeding $11.6 billion [9]. - Mounjaro's Q4 revenue reached $7.41 billion, a staggering 110% increase year-over-year, while Zepbound achieved $4.26 billion, a 123% increase [12]. Sales Strategy - Eli Lilly's growth is driven by volume, with global product sales increasing by 46% in Q4, offsetting a 5% decline in realized prices [12]. - In the U.S. market, sales volume surged by 50%, despite a 7% drop in actual prices, reflecting strategic pricing adjustments to expand patient access [12]. Market Position - Eli Lilly's optimistic outlook starkly contrasts with Novo Nordisk's warning of a potential 13% decline in sales due to intensified price competition [15]. - The company is expected to maintain over 20% growth in 2026, even with a high revenue base of $65.18 billion in 2025 [15]. R&D and Capacity Expansion - Eli Lilly is advancing its pipeline with a focus on convenient administration methods and expanding indications, including an oral weight loss drug awaiting regulatory approval [19]. - The company is investing heavily in production capacity, including a new injection facility in Pennsylvania and a $6 billion active pharmaceutical ingredient plant in Alabama [19]. Financial Metrics - The gross margin is reported at 82.5%, with a non-GAAP margin of 83.2%, benefiting from favorable product mix and improved production costs [20]. - R&D expenses increased by 26% to $3.8 billion, representing 20% of revenue, while SG&A expenses rose by 29% to $3.1 billion, also 20% of revenue [20].

分析师周五分享的艾昆纬数据显示，诺和诺德口服版司美格鲁肽（Wegovy）在美国上市后第二个完整 交易周的处方量突破 2.6 万张。 减肥药市场竞争激烈，投资者正密切关注该药物的处方数据，以此观察这家丹麦药企能否凭借先发优 势，在与竞争对手礼来的较量中占据上风。 分析师周五分享的艾昆纬数据显示，诺和诺德口服版司美格鲁肽（Wegovy）在美国上市后第二个完整 交易周的处方量突破 2.6 万张。 减肥药市场竞争激烈，投资者正密切关注该药物的处方数据，以此观察这家丹麦药企能否凭借先发优 势，在与竞争对手礼来的较量中占据上风。 巴克莱分析师在研报中指出，截至 1 月 23 日的一周，口服版司美格鲁肽的处方量达 26109 张，这一数 据表明这款口服药的上市首秀表现十分亮眼。 这款药物于 1 月 5 日在美国上市，上市后前四天的处方量为 3071 张；在截至 1 月 16 日的首个完整交易 周，其处方量便突破 1.8 万张。 责任编辑：郭明煜 巴克莱分析师在研报中指出，截至 1 月 23 日的一周，口服版司美格鲁肽的处方量达 26109 张，这一数 据表明这款口服药的上市首秀表现十分亮眼。 这款药物于 1 月 5 日在美 ...

Core Viewpoint - Eli Lilly's new weight loss drug orforglipron is expected to be approved for market launch this quarter, with the company prepared to meet market demand [1] Group 1: Drug Approval and Market Readiness - Orforglipron received priority review status from the FDA in November last year, significantly shortening the review period from the standard 10-12 months to just 1-2 months [1] - The company submitted the formal application for the drug's market approval to the FDA in December [1] - Eli Lilly plans to initiate the launch process simultaneously in multiple countries globally as soon as approval is granted [1] Group 2: Investment and Pricing Strategy - The company has invested hundreds of millions of dollars in building production facilities for orforglipron [1] - The initial monthly price for self-paying patients is set at $149, with higher dosage options increasing the monthly cost to $399 [1] Group 3: Competitive Landscape - Upon approval, orforglipron will face competition from Novo Nordisk's oral weight loss drug Wegovy, which was launched in early January at a similar initial self-pay price [1]

Core Viewpoint - Novo Nordisk (NVO.US) has seen a significant stock price increase, rising over 4% in pre-market trading and accumulating an 8% increase over the previous two days, currently priced at $57.33. This surge is attributed to the announcement of the launch of two oral weight loss medications, Wegovy, for self-paying patients in the U.S. starting January 5 [1] Pricing and Product Details - The two initial dosages of Wegovy, 1.5 mg and 4 mg, will be priced at $149 per month. Additionally, two higher dosage forms, 9 mg and 25 mg, will be available at a monthly price of $299 [1] - The price for the 4 mg dosage will increase to $199 per month starting April 15 [1] Regulatory Approval and Market Position - The U.S. Food and Drug Administration (FDA) approved the oral medication Wegovy on December 22 of the previous year, providing Novo Nordisk with a renewed competitive edge against Eli Lilly (LLY.US) in the market [1]

Core Viewpoint - After experiencing a significant drop in stock price and losing its title as the "king of weight loss drugs," Danish pharmaceutical giant Novo Nordisk is attempting to regain market dominance through a bold political maneuver and accelerated product strategy [1]. Group 1: Political Deal and Pricing Strategy - Novo Nordisk has reached a crucial agreement with the Trump administration to significantly lower the prices of its flagship weight loss drug under U.S. federal healthcare programs, in exchange for a three-year exemption from import tariffs and expedited FDA review for its high-dose Wegovy injection [1][5]. - The agreement will expand insurance coverage for weight loss drugs, previously limited to patients with specific comorbidities, to include overweight individuals with prediabetes [5]. Group 2: Market Position and Competitive Advantage - The FDA has approved the oral version of Wegovy, which is set to launch in January 2026, allowing Novo Nordisk to lead the oral weight loss drug market ahead of Eli Lilly's similar product, expected to be approved in March 2026 [1][7]. - Novo Nordisk's new CEO, Mike Doustdar, has confirmed that the company is well-prepared for the launch and is negotiating with telehealth platforms to expand sales channels [7]. Group 3: Financial Performance and Valuation - Despite potential short-term sales growth pressure due to price concessions, investors are reassessing Novo Nordisk's valuation, which has dropped significantly, with a projected P/E ratio of about 14 times, half of its five-year average [4][12]. - The company's stock price had previously plummeted over 50% in 2025 due to disappointing clinical trial results and competition from Eli Lilly's Zepbound, but the recent political deal and new drug approvals are seen as a strategic turnaround [4][8]. Group 4: Market Challenges and Strategies - Novo Nordisk faces a significant challenge from a burgeoning market of cheap generic GLP-1 drugs, with over 1 million patients in the U.S. using these alternatives [13]. - To reclaim market share, Novo Nordisk has launched the NovoCare platform, offering substantial discounts to self-paying users, aiming to convert "black market" users into legitimate customers [13].